On 7 March 2025, AstraZeneca announced that India’s Central Drugs Standard Control Organisation (CDSCO) has approved its Imfinzi® (durvalumab) 120 mg/2.4 mL and 500 mg/10 mL solution for infusion, for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
In February this year, the EU’s CHMP recommended Imfinzi® for the new indication of treating adults with resectable NSCLC at high risk of recurrence, and in January, recommended Imfinzi® for LS-SCLC.
Also in February 2025, Australia’s TGA is accepted for review an indication expansion of Imfinzi® for muscle invasive bladder cancer, and was approved for LS-SCLC later thatd month.
In January 2025, the UK’s NICE recommended Imfinzi® in combination with chemotherapy (etoposide) plus either carboplatin or cisplatin for the treatment of adults with untreated extensive- SCLC